创新药深度回调，可以上车吗？高人气520880跌逾3%，溢价高企，近4日吸金6．7亿元

Core Viewpoint - The Hong Kong Stock Exchange's innovative drug ETF (520880) has experienced significant inflows and price increases, indicating strong market interest and potential growth in the innovative drug sector [1][4]. Group 1: ETF Performance - The innovative drug ETF (520880) has seen a price increase of 3.38% recently, with a premium rate of 0.46%, reflecting strong buying interest [1]. - Over the past four days, the ETF has attracted a net inflow of 673 million yuan, bringing its total size to 97.4 billion yuan, a 124% increase since its launch on July 7 [1][4]. - The ETF passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which focuses on the innovative drug industry chain with a high concentration of leading companies [4]. Group 2: Index Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has risen by 101.58% year-to-date as of July 31, outperforming the Hang Seng Index (23.50%) and the Hang Seng Technology Index (22.05%) by 78.08 and 79.53 percentage points, respectively [5][6]. - The index has shown significant volatility in previous years, with annual returns of -22.72% in 2021, -16.48% in 2022, -19.76% in 2023, and -14.16% in 2024 [6]. Group 3: Market Outlook - Analysts believe that the innovative drug sector is poised for growth due to improving policies and the maturation of research pipelines, which are expected to enhance the competitiveness of Chinese innovative drugs globally [7]. - The recent measures to support high-quality development in innovative drugs are anticipated to further bolster the sector, with a focus on innovation, internationalization, and marketing reforms [7].